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The cottontail rabbit papillomavirus (CRPV)/rabbit model has been used to study oncogenicity and immunogenicity of different antigens from
the papillomavirus genome and has therefore served as a preclinical model for the development of preventive and therapeutic vaccines against
papillomavirus infections. One unique property of the CRPV model is that infection can be initiated using viral DNA. This property allows for the
functional testing of viral mutants in vivo. We have introduced point mutations, insertions and deletions into all of the different coding and non-
coding regions of the CRPV genome and have tested their infectivity in this model. We found that the majority of the mutant genomes retained
viability and could induce papillomas in domestic rabbits. These data indicated that the CRPV genome is tolerant of many modifications without
compromising its ability to initiate skin papillomas. In combination with our recently established HLA-A2.1 transgenic rabbit model, this
plasticity allows us to extend the utility of the CRPV/rabbit model to the screening of HLA-A2.1 restricted epitopes from other human viral and
tumor antigens.
© 2006 Elsevier Inc. All rights reserved.Keywords: CRPV; Modification; Mutants; DNA challenge; Functional studyIntroduction
Human papillomaviruses (HPVs) are small DNA tumor
viruses which cause skin and genital warts in the human
population (zur Hausen, 2000). More than 100 different
genotypes have been identified to date. These viruses cause
infections in both cutaneous and mucosal tissues and their
infections are highly species and tissue specific (Bosch et al.,
2002). Therefore, no in vivo animal model is available to study
HPV infection in immunocompetent hosts.
An effective animal model is essential to study viral–host
interaction in vivo. Several animal models are utilized
extensively in papillomavirus research (Campo, 2002). Cotton-⁎ Corresponding author. Microbiology and Immunology Department, Penn-
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doi:10.1016/j.virol.2006.08.045tail rabbit papillomavirus (CRPV) was the first identified animal
papillomavirus and the CRPV/rabbit model system has been
one of the most widely used (Christensen, 2005). The CRPV/
rabbit model has added value because CRPV-induced cancer
mimics the progression and metastases of HPV-induced tumors
in the human population (Christensen et al., 2000).
We have worked with the CRPV/New ZealandWhite (NZW)
rabbit model system for many years and have developed
refinements including an improved DNA infectivity technique
which has allowed us to study viral mutants in the context of the
domestic rabbit without the requirement for infectious virions.
This approach allows us to test different mutants for infectivity
studies in vivo based on the monitoring of tumor development
and the histological assessment of lesions. Our infectivity assay is
based predominantly onwhether or not the constructs are capable
of inducing papillomas on animals. Any constructs which are
able to induce papilloma growth are identified as infectious
constructs while those that are unable to induce papillomas on
animals are identified as dysfunctional or non-viable constructs.
Table 1
Representative CRPV mutants list
Construct
name
Mutation
site
Mutation information
E1m#1 E1 CRPVE1 sequence 3128–3170 bp replaced by
corresponding ROPVE1
E1m#2 CRPVE1 sequence 1999–2017 replaced by
corresponding ROPVE1
E2m#1 E2 CRPVE2 sequence 4021–4283 bp replaced by
corresponding ROPVE2
E2m#2 CRPVE2 sequence 3128–3382 bp replaced by
corresponding ROPVE2
E5m#1 E5 CRPVE5/E8 double ATG mutant with wild type
E8 at NsiI
E5m#2 CRPVE5 ATG mutant with 314 bp fragment of
HSV-tk gene in the sense orientation at NsiI
E5m#3 CRPV with a deletion of 4300–4344 bp in E5
E6m#1 E6 CRPVE6 with new enzyme sites engineered at
326 bp/MscI and 476 bp/HpaI
E6m#2 CRPV E6 and E7 replaced by ROPVE6 and E7
E6m#3 CRPVE6 fragment 326–476 bp replaced
by corresponding ROPV fragment
E6m#4 CRPVE6 fragment 326–973 bp replaced
by corresponding ROPV fragment
E6m#5 CRPVE6 fragment 476–973 bp replaced
by corresponding ROPV fragment
E7m#1 E7 CRPVE7 point mutation resulting in S21 to G
E7m#2 CRPVE7 point mutation resulting in S21 to D
E7m#3 CRPVE7 point mutation resulting in R57 to S
E7m#4 CRPVE7 replaced by CRPV regressive strain E7
E7m#5 CRPVE7 containing HPV16E7/82–90 epitope
LLMGTLGIV
URRm#1 URR CRPV with 7732–7786 deletion and a mutation
in the 8th E2 binding site
URRm#2 Replacement of CRPVURR with ROPVURR
at engineered enzyme sites BsiW1/7380 and
SacII/152
URRm#3 Deletion of URR7671–7798 fragment)
URRm#4 CRPVURR with four additional E2 binding
sites at BglII
URRm#5 CRPVURR with two copies of ROPVURR
7458–7556 bp fragment in sense orientation
at BglII
URRm#6 CRPVURR with full length of ROPVURR
inserted at BglII
URRm#7 CRPVURR with a deletion of the 5′-most E2
binding site 7420–7466 bp
URRm#8 CRPVURR with insertion of a 314 bp
fragment of the HSV-tk gene at BglII
URRm#9 CRPVURR with two additional E2 binding
sites at BglII
URRm#10 CRPVURR with six additional E2 binding
sites at BglII
385J. Hu et al. / Virology 358 (2007) 384–390The rationale for the choice and construction of the different
mutations described in this study, mutations that are scattered
throughout the CRPV genome, can be defined by several broad
research goals. First of all, we wished to identify those genes
essential for CRPV function in vivo using ATG knockouts or
early stop codon mutations. Second, we wanted to explore two
major fundamental questions of papillomavirus biology: (1)
what are the factors controlling the tissue specificity of
papillomavirus infection? and (2) what gene or gene region
contributes to the benign versus malignant phenotypes of the
papillomas? We have two distinct types of rabbit papilloma-
viruses for our studies; one is CRPV which induces skin tumors
and the other is rabbit oral papillomavirus (ROPV) which
induces mucosal tumors. These two viruses share the highest
homology in their genome coding proteins when compared with
other papillomaviruses (Hu et al., 2004). We are interested in
determining which region controls the tissue specificity of these
viruses, and these studies provide the rationale for construction
of numerous fragment replacements using CRPV and ROPV
sequences (Table 1). In addition to having two distinct types of
rabbit papillomaviruses, we also have two distinct phenotypes
or strains of CRPV that are naturally occurring variants (Salmon
et al., 2000). One strain is designated a progressive strain
(CRPVp) in which papillomas persist and progress. The second
strain is termed a regressive strain (CRPVr) in which papillomas
regress at high rates in both inbred and outbred rabbits. Our goal
with these two viral strains was to define the region of the
genome that plays a dominant role in discriminating between
the two outcomes of infection. In our previous publications, we
reported that the carboxy-terminal region of CRPV E6
controlled regression (Hu et al., 2002a). However, since
ROPV infection generates benign papillomas which quickly
regress, we therefore constructed CRPV/ROPV hybrid E6
genes in the CRPV backbone to test whether such hybrid genes
could function in vivo and lead to regression. (Hu et al., 2004).
We have created point mutants, insertions and deletions and
have tested their infectivity and, in some cases, their malignant
potential in rabbits. Using ATG knockout technology and
introducing early stop codons, we have demonstrated that E1,
E2, E6 and E7 are essential for papilloma outgrowth in rabbits.
These findings are consistent with earlier reports (Wu et al.,
1994; Jeckel et al., 2002). In addition, we confirmed that the L2
protein is dispensable for papilloma growth (Nasseri et al.,
1989). On the other hand and contrary to earlier reports, we
found that the L1 protein is also dispensable for papilloma
formation (Nasseri et al., 1989). We found that both E4 and E5
are dispensable for papilloma outgrowth confirming earlier
reports. (Peh et al., 2004; Brandsma et al., 1992). However, in
contrast to previous reports (Meyers and Wettstein, 1991;
Nonnenmacher et al., 2006), E8 and SE6 were not essential for
tumor growth but such mutations led to smaller and slower
growing tumors (Christensen, 2005). We also observed that
many deletions, insertions and point mutations in individual
genes could be introduced without destroying the ability of the
genome to generate papillomas. Our findings have also
demonstrated that portions of foreign genes can be inserted
into the CRPV genome and that these mutants can still inducetumors in rabbits. Our system allows us, therefore, to study both
oncogenicity and immunogenicity of modified genomes in the
context of the live animal and to investigate the mechanism of
papillomavirus induced malignancy in vivo. The purpose of this
study is to present the collective observations of our studies on
CRPV mutations in the unifying context of (a) the same CRPV
genetic strain; (b) a series of genetic mutations in all ORF and
non-coding regions; and (c) identical infection procedures for
comparative studies within the same research laboratory. These
findings demonstrate that significant mutations are tolerated in
Table 2
Function and tumor growth of CRPVATG knockout and early stop mutants
Gene ATG
knock out
Early stop
codon
Animal
Numbers
Papillomas/
challenge sites
E1 + 4 0/8
E2 + 4 0/8
E6 + 4 0/8
E7 + 8 0/16
SE6 + 3 2/6
E8 + (Hu et al., 2002b)
E4 + 4 8/8
E5 + 4 10/12
E5/E8 + 4 12/12
L1 + 2 10/10
L2 + 4 12/12
386 J. Hu et al. / Virology 358 (2007) 384–390the CRPV genome, and provide opportunities for studies on
host/virus interactions, immunogenicity, oncogenicity and
tissue tropism in vivo in immunocompetent animals.
Results
CRPV DNA challenge induced papillomas comparable to those
induced by virus infection in domestic rabbits
Hershey CRPV cloned into PUC19 at SalI/4572 (wild type
CRPV) has been demonstrated to be infectious in domestic
rabbits. We conducted a comparative study with rabbits
challenged with viral DNA and infectious virus stock (1:100,
a dose used for most of our previous infection studies). Three
NZW rabbits were challenged at four left back sites with virus
stock (1:100) and at four right back sites with viral DNA
(10 μg). Papilloma outgrowth was monitored and recorded.
All challenge sites grew papillomas from both viral DNA and
virus infection. Tumors induced by viral DNAwere significantly
smaller when compared with those induced by virus infection
(P<0.05, unpaired Student's t test) in the first several weeks.
But no significant difference in tumor size was found after week
9 of infection (P>0.05, unpaired Student's t test, Fig. 1).
Therefore, our method of viral DNA infection was efficient in
domestic rabbits.
E1, E2, E6 and E7 but not other early and late genes are
essential for papilloma outgrowth in rabbits
To determine which genes were critical to the induction of
papilloma growth in rabbits, we generated ATG knockout and
early stop codon mutants for each individual gene. Our results
are summarized in Table 2. E1, E2, E6 and E7 were essential
for tumor growth. In contrast, short E6 (SE6), E8, E4, E5, L1Fig. 1. Papilloma outgrowth after CRPV infectious virions (1:100) and DNA
(10 μg) challenge on three outbred rabbits. Four left and right back skin sites
were challenged with infectious virions and viral DNA respectively (N=12).
Papillomas induced by virions were significantly larger when compared with
those induced by CRPV DNA infection before week 9 after challenge (P<0.05,
unpaired Student's t test). No significant difference was found in the papilloma
size between these two challenge methods after week 10 (P>0.05, unpaired
Student's t test).and L2 were not required for papilloma outgrowth (Table 2).
However, papilloma growth rates were diminished by SE6
(Fig. 2) and E8 ATGko mutations (Hu et al., 2002b). E8ATGko
mutant infectious virus was generated in wild cottontail rabbits
and the mutant virus showed slower papilloma growth when
compared with that of wild type virus but all challenge sites grew
papillomas (Christensen, 2005). No significant difference in
growth rates was found between E4 mutant and E5 ATGko and
wild type CRPV-induced papillomas (data not shown).
E1, E2, E6 and E7 could be modified without loss of papilloma
formation
The ATG knockout and early stop codon mutants showed
that E1, E2, E6 and E7 were essential for papilloma outgrowth.
We next wanted to test if we could introduce mutations into
these individual genes without loss of papilloma formation.
Point mutations (changing one or two amino acid residues) and
hybrids (replacement of a defined region of amino acids withFig. 2. Papilloma outgrowth after wild type CRPV, CRPV hybrid with regressive
strain E7 (E7r) and CRPVSE6ATGko DNA challenge in four EIII/JC inbred
rabbits. Two sites/per construct/per animals were challenged with wild type
CRPV, CRPVE7r and CRPVSE6ATGko respectively (N=8). CRPVE7r hybrid
infection showed a similar papilloma growth pattern to that of the wild type
CRPV (P>0.05, unpaired Student's t test). Significantly smaller papillomas
were induced by CRPVSE6ATGko infection when compared to those induced
by the wild type CRPV (P<0.01, unpaired Student's t test).
Table 3
Function and tumor outgrowth of CRPV early gene hybrids
Construct Animal
Numbers
Papillomas/
Challenge sites
Cancer development
(>14 months)
E1m#1 2 6/6 ND
E1m#2 2 7/8 ND
E2m#1 4 12/12 ND
E2m#2 2 6/6 ND
E5m#1 2 7/8 ND
E5m#2 2 7/8 ND
E5m#3 2 8/8 ND
E6m#1 3 6/6 ND
E6m#2 2 0/6
E6m#3 2 0/6
E6m#4 4 0/8 (Hu et al., 2004)
E6m#5 4 0/8
E7m#1 2 6/6 0/6
E7m#2 2 6/6 4/6
E7m#3 2 6/6 2/6
E7m#4 4 6/6 ND
E7m#5 5 15/16 ND
ND—not determined.
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genes (Table 3). Although we have noted some replacements
that were lethal to CRPV genome function, many changes in
these genes did not affect the ability of the genome to induce
papillomas.
A panel of mutants in the CRPV progressive strain (wild type
CRPV) E6 gene has been reported previously (Hu et al., 2002a).
The compatibility between wild type CRPVE6 and a regressive
CRPV strain (CRPVr) E6 was very high and CRPV regressive
strain E7 replacement in CRPV also produced papillomas at
wild type rates (Fig. 2, Table 3). However, the E6 and E7 genes
of CRPV and rabbit oral papillomavirus (ROPV) were not
interchangeable. Several genomes containing hybrid CRPV-Fig. 3. Papilloma outgrowth after wild type CRPV and a CRPV mutant
containing an HLA-A2.1 epitope of HPV16E7 (LLMGTLGIV, amino residues
82–90) DNA infection in four outbred rabbits. Four left and right back skin sites
were challenged with wild type CRPV and CRPV-HPV16E7/82–90 (N=16).
Significantly smaller papillomas were induced by CRPV-HPV16E7/82–90
when compared with those induced by the wild type CRPV (P<0.05, unpaired
Student's t test).ROPV E6 and E7 genes were also dysfunctional (Hu et al.,
2004) (Table 3).
We had made several point mutants in CRPV E7 based on
the findings that E7 amino acid position 21 played an important
role in transforming activity in vitro (Edmonds and Vousden,
1989). We hypothesized that changing S21 of CRPV E7 to G or
D would result in a more benign (G) or malignant (D)
phenotype. Our results correlated with this prediction although
no significant difference was found between these mutants
when compared with the wild type genome because only limited
numbers of animals was used. A second point mutation (R57S)
which resulted in a large sidechain change at this position
showed a phenotype similar to that of the wild type CRPV. In
addition, we generated HPV16 E7/82–90 (LLMGTLGIV, an
HLA-A2.1 restricted epitope) (Kast et al., 1993) hybrid in the
CRPV genome and this mutant genome generated papillomas.
The papillomas were significantly smaller when compared to
those induced by wild type CRPV (Fig. 3, P<0.05, unpaired
Student's t test). These data indicate that it is possible to embed
an HLA-A2.1 restricted epitope from another virus or antigen
into a CRPV gene in the context of the whole CRPV genome
and retain the function of papilloma induction.
The CRPV E5 gene can be modified extensively
The CRPV E5 gene was previously identified as an
oncogene (Han et al., 1998). However, our studies of the
ATG mutant as well as the studies of other investigators have
indicated that E5 is dispensable for CRPV infection (Brandsma
et al., 1992). In addition to these findings, we have found that
E5 may contain regulatory elements. For example, the insertion
of a SnaB1 site at 4292 bp with no change in amino acid
sequence to E5 resulted in a non-viable genome. We were also
able to insert the CRPV E8 gene and a fragment of the HSV-tkFig. 4. Papilloma outgrowth after wild type CRPV, CRPVL1ATGknockout
mutant and CRPV/ROPVL1 hybrid DNA challenge in four EIII/JC inbred
rabbits. Four sites/per animal were challenged with each constructs respectively
(N=16). The CRPVL1ATGko mutant induced significantly larger papillomas
when compared with those induced by wild type CRPV (P<0.05, unpaired
Student's t test). Significantly smaller and fewer papillomas were induced by
CRPV/ROPVL1 hybrid infection when compared to those induced by wild type
CRPV (P<0.01, unpaired Student's t test).
388 J. Hu et al. / Virology 358 (2007) 384–390gene into E5 without disrupting papilloma formation by these
constructs (Table 3).
L1 and L2 proteins are dispensable but the DNA sequences are
required for tumor outgrowth
Neither the L1 nor the L2 ATGko mutations prevented
induction of tumors in rabbits (Table 2). Interestingly, the
L1ATGko induced significantly larger papillomas when
compared to those induced by wild type CRPV (Fig. 4,
P<0.05, unpaired Student's t test) in EIII/JC inbred rabbits. No
significant difference in growth was found between the
L2ATGko and wild type CRPV papillomas based on the
limited numbers of animals in which this construct was tested.
To further delineate the role played by these two genes in
papilloma formation, we made a mutant in which the entire
region containing the L1 and L2 genes was deleted. This double
deletion mutant was non-viable. Therefore, although L1 and L2
proteins are not critical to papilloma induction in rabbits, these
genes appear to contain essential elements. Next, we exchanged
the CRPV L1 gene for that of ROPV, which shares significant
homology with its CRPV counterpart. 11 out of 12 sites infected
with the CRPV/ROPVL1 hybrid genome grew papillomas in 4
NZW outbred rabbits. In contrast, 50% of the sites challenged
by this CRPV/ROPVL1 hybrid grew tumors in EIII/JC inbred
rabbits and these tumors were significantly smaller than those
generated by wild type CRPV (Fig. 4, P<0.01, unpaired
Student's t test). Regression was also noticed in these tumors.
Upstream regulatory region (URR) was tolerant of different
modifications
In view of our findings that there was considerable plasticity
in the CRPV coding regions, we were interested to determine
whether the upstream regulatory region (URR) exhibited similar
tolerance to mutation. The Hershey CRPV URR contains eight
E2 binding sites (E2BS) as well as numerous other putative
regulatory elements. A panel of deletions or insertions of
different E2 binding sites did not influence tumor development
in animals (Table 4). One hybrid in which we replaced the
CRPV URR with that of ROPV was dysfunctional (Table 4).
However, a hybrid with an insertion of the entire ROPV URR
into the CRPV URR produced papillomas. We also found that
the region of the CRPV URR between 7671 and 7798 wasTable 4
Function of papilloma outgrowth of CRPV URR mutants
Construct Animal numbers Papillomas/Challenge sites
URRm#1 2 1/4
URRm#2 1 0/4
URRm#3 2 0/6
URRm#4 1 6/6
URRm#5 1 6/6
URRm#6 2 6/6
URRm#7 2 6/6
URRm#8 2 12/12
URRm#9 2 6/6
URRm#10 2 6/6essential because deletion of this sequence prevented papilloma
formation. A final observation was that the CRPV URR
remained functional following an insertion of foreign non-viral
DNA (Table 4). These insertions were retained in the DNA
isolated from papillomas as determined by PCR amplification
and subsequent sequencing of the PCR products. Interestingly,
we also found sequences in the amplimers that indicated that the
foreign element had been eliminated. These bands indicating
the latter scenario were always a minor component of the
amplification.
Deletion and insertions in the “non-coding” region between
the E6 and E7 genes
We observed that a region between CRPVE6 and E7
contained a small coding sequence for a putative 40 aa protein
in a different reading frame. We named this candidate gene E10.
We made an ATG knockout of this putative gene in an attempt
to determine if it had any significance in the papillomavirus life
cycle. Our results showed that no change in papilloma
formation and outgrowth occurred following infection with
this E10ATGko mutant. A second mutation was made which
represented a deletion of about 90 bp of the putative E10 coding
region (CRPVE10del). Five out of 10 papillomas in 4 NZW
outbred rabbits and 6 out of 12 papillomas in 3 EIII/JC inbred
rabbits induced by CRPVE10del regressed. In addition to
higher rates of regression, this mutant showed a reduced growth
rate when compared to wild type CRPV-induced papillomas. A
mutant genome with an insertion of EGFP in this region was
dysfunctional.
Discussion
The CRPV/rabbit model has been widely used in different
laboratories. Data accumulated in our laboratory over a number
of years have indicated that the CRPV genome can tolerate
significant modifications. These observations have provided
valuable insights into the genetics of the papillomavirus and
have provided new opportunities for the application of this
model system. Our data have shown that the early genes E1, E2,
E6 and E7 are essential for tumor development in rabbits which
is consistent with previous reports (Wu et al., 1994). These
genes, however, were shown to be tolerant of some modifica-
tions without compromising function. Other early genes
including E4, SE6 and E8 are not essential but phenotypic
changes were induced (Peh et al., 2004; Hu et al., 2002a). Our
data showed that the E5 ATGko exhibited the same phenotype
as wild type. Consistent with others, however, we also found
that a regulatory element within this putative gene was critical
for CRPV genome function (Brandsma et al., 1992). Late gene
products (L1 and L2) were not required for papilloma
development but the DNA sequence had to be present for
successful infections. The URR could not be replaced but could
be modified extensively without destroying CRPV genome
function. Taken together, these results show that the CRPV
genome is very tolerant to modification and therefore has
significant potential as a surrogate vector to screen epitopes
Fig. 5. Genetic map of the circular CRPV genome. E6, SE6, E7, E2 and L2 are
coded from the open reading frame 1, E8, E4, E5 and L1 are coded from the
open reading frame 2 and E1 is from the open reading frame 3. The CRPV
genome used for DNA challenge and mutant generation is cloned in PUC19 at
single enzyme site in E5 (SalI 4572).To standardized the results, all the mutants
were based on Hershey progressive CRPV strain reported in our previous
studies. Every mutation was confirmed by DNA sequence analysis. * New
enzyme sites generated for the convenience of cloning.
389J. Hu et al. / Virology 358 (2007) 384–390from other viral genomes when combined with our recently
developed HLA-A2.1 transgenic rabbit system.
We and others have demonstrated that CRPV DNA cloned
into a plasmid is infectious in domestic rabbits. Different
delivery methods have been utilized and varying efficiencies
noted (Lin et al., 1993; Brandsma et al., 1991; Brandsma and
Xiao, 1993; Kreider et al., 1995; Xiao and Brandsma, 1996;
Salmon et al., 2000). In many cases, low infection rates and high
variations in papilloma sizes were found in these early studies.
In our previous DNA infection studies we used a pre-treatment
strategy to achieve very high efficiency of papilloma induction
(Hu et al., 2002a). However, variations in papilloma size and
growth rates were still observed. We noted also that the same
construct could show different growth rates and regression
profiles depending upon the strain of animals used (Hu et al.,
2002a). The modified infection method recently established in
our laboratory improves the consistency of the results in both
inbred and outbred strains of animals used in our experiments
and has the added advantage of being safer to use. The method
consists of wounding sites 3 days prior to the delivery of DNA.
The establishment of a wound-healing environment at the time
of viral DNA challenge has been shown to greatly enhance
efficiency of papilloma induction and has resulted in highly
consistent results (manuscript in preparation).
Many early studies using genetically modified CRPV were
hampered by technological limitations and primarily involved
deletions, which could be generated with technologies existing
at the time. In the present studies, we tested the function of each
gene by generating ATG knockout or early stop codon mutants,
which did not otherwise perturb the DNA sequence of each
gene. We noticed that these two mutational approaches resulted
in different outcomes that could lead to different interpretations.
Dysfunction resulting from deletion of a portion of a gene
could result from the inadvertent deletion of a cryptic regulatory
element as well as a disruption of the integrity of the gene
product. An example of this phenomenon can be seen in studies
with the L1 gene. We demonstrated in this paper that CRPVL1
was dispensable for CRPV infection; that replacement of CRPV
L1 with ROPV L1 reduced papilloma growth rates, and that
deletion of the entire L1 gene resulted in dysfunction. Similar
results were found for the putative gene E10. Although an ATG
knockout did not prevent papilloma formation, deletion of this
region resulted in a significant phenotypic change (slower
growth rate and regression of papillomas). We conclude that our
modified infection method provides a unique opportunity to
investigate the function of different papillomavirus genes in
vivo in a more reproducible manner.
Demonstration of the considerable plasticity of the CRPV
genome will aid our continuing efforts to understand the life
cycle of this virus. The flexibility of the genome will also
provide opportunities for the development of therapeutic targets
for treatment against viral infection. Furthermore, we can also
use this model to test the expression potential of specific
epitopes of human pathogens and can potentially use the CRPV
genome as a vector to test immunogenicity of the epitopes in our
in vivo system. We have recently developed an HLA-A2.1
transgenic rabbit model that will help us to screen hostimmunity targets from the HPV genome (manuscript in
revision). With the successful engineering of candidate epitopes
into the CRPV genome, testing in the context of our HLA-A2.1
rabbits will become a very promising preclinical model system
for immunotherapeutic studies.
Methods and materials
Constructs
Hershey progressive strain CRPV (CRPVp, Fig. 5) cloned
into PUC19 at SalI was identified as wild type CRPV and used
as the backbone for most mutants. Hershey regressive CRPV
strain (CRPVr) and rabbit oral papillomavirus (ROPV) genes
were cloned into PUC19 as previously described (Hu et al.,
2002a) (Hu et al., 2005). Herpes Simplex virus thymidine
kinase (HSV-tk) gene was provided by Dr. Kristin Eckert of
Pennsylvania State Hershey Medical Center. Mutant constructs
were categorized as site mutations, hybrids, insertions or
deletions. For the convenience of cloning and handling, each
individual gene was cloned into PUC19 for subsequent
modification. Point mutations and deletions were introduced
into each gene by using a QuickChangeTM site-directed
mutagenesis kit (Stratagene, La Jolla, CA). Other insertions
and replacements were made with routine restriction digest and
ligation technology strategy. All the mutations were confirmed
by DNA sequence analysis at the Core Facility of Pennsylvania
State University Hershey Medical Center. Representative
mutants reported in this paper are shown in Table 1.
DNA challenge and monitoring of tumors
The constructs were purified by cesium chloride ultracentri-
fugation and adjusted to 200 μg/ml in 1× TE buffer (Hu et al.,
390 J. Hu et al. / Virology 358 (2007) 384–3902002a) for challenge on animals. New Zealand White (NZW)
rabbits and EIII/JC inbred rabbits were maintained in the animal
facility of the Pennsylvania State University College of
Medicine. The studies were approved by the Institutional
Animal Care and Use Committee of the Pennsylvania State
University. For application of virus and viral DNA, rabbits were
sedated using ketamine/xylazine anesthesia. Back skin of the
animals was scarified with a scalpel blade and superficially
scratched. Three days later, the wounded sites were scratched 20
times with a 21-G needle to introduce small abrasions into the
scab. Each site was then challenged with 10 μg DNA in 50 μl
of 1× TE buffer (Hu et al., 2002a). Monitoring of papilloma
outgrowth began 3 weeks later and continued until week 12.
In some cases, the animals were kept to monitor cancer
development. Papilloma biopsies were collected after animal
sacrifice and H&E staining was conducted for histological
examination.
Statistics
Papilloma size was determined by calculating the cubic
root of the product of length×width×height of individual
papillomas in millimeters to obtain a geometric mean
diameter (GMD). Data were represented as the means
(+SEMs) of the GMDs for each test group. Statistical
significance was determined by unpaired t test comparison
(P<0.05 was considered significant).
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